Paper
0
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Authors
Patrick Forde,Jonathan Spicer
Shun Lü,Mariano Provencio,Tetsuya Mitsudomi,Mark Awad,Enriqueta Felip,Stephen Broderick,Julie Brahmer,Steven Swanson,Keith Kerr,Changli Wang,Tudor–Eliade Ciuleanu,Gene Saylors,Fumihiro Tanaka,Hiroyuki Ito,Ke‐Neng Chen,Moïshe Liberman,Everett Vokes,Janis Taube,Cécile Dorange,Junliang Cai,Joseph Fiore,Anthony Jarkowski,David Balli,Mark Sausen,Dimple Pandya,C. Calvet,Nicolas Girard,Tudor‐Eliade Ciuleanu
+28 authors
,Ke-Neng ChenPublished
Apr 11, 2022
Show more
Save
Tip0
TipSave
Abstract
Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.